Physician profile
Richard E Vasicek
NPI 1316037146
$3,590.18
in general payments reported to CMS, 2019-2025
24 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $433 · 2021: $467 · 2022: $572 · 2023: $794 · 2024: $539 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $786.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $615.57 | 2019-2025 | |
| Abbvie INC. | $451.34 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $446.02 | 2020-2025 | Farxiga, Brilinta |
| Exact Sciences Corporation | $234.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $143.17 | 2019-2023 | Mounjaro, Trulicity |
| Abbott Laboratories | $122.35 | 2023-2025 | Freestyle Libre 3, Amplatzer Amulet |
| Glaxosmithkline, LLC. | $118.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $96.13 | 2020-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $84.37 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $79.76 | 2019-2025 | |
| Allergan, INC. | $68.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $56.68 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2023-2024 | Jardiance, Tradjenta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30.71 | 2022 | |
| Merck Sharp & Dohme LLC | $30.57 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.13 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $25.94 | 2023 | Nuedexta |
| Medicure Pharma INC. | $19.01 | 2022 | |
| Viatris Specialty LLC | $16.30 | 2025 | Yupelri |
| Dexcom, INC. | $15.45 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $15.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Vasicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.